Company information
- Ticker
- USAQ
- Country
- United States
- Sector
- Health Care
- Industry
- Medtech
QHSLab Business Summary
QHSLab, Inc. (USAQ) is a digital health infrastructure company that provides primary care physicians with a suite of AI-driven screening tools and point-of-care diagnostic tests designed to enhance preventive care and practice revenue. The company generates revenue through its Integrated Service Program (ISP), which utilizes a Software-as-a-Service (SaaS) model for digital health assessments—such as the Q-Cog™ cognitive screening tool—and the sale of proprietary medical devices like the AllergiEnd® diagnostic system. Its business is segmented into digital medicine applications, which facilitate reimbursable clinical workflows for chronic disease management, and rapid-response point-of-care diagnostics. QHSLab competes with digital health and medical technology firms such as Firefly Neuroscience (AIFF), Biotricity (BTCY), VSee Health (VSEE), and Bullfrog AI Holdings (BFRG), positioning itself as a turnkey, low-IT-barrier solution specifically tailored for the approximately 263,000 independent primary care practices in the United States. The leadership team is headed by Chairman and CEO Troy Grogan, a medical device manufacturer and healthcare technology veteran who previously oversaw one of Australia’s largest health systems in Sydney. Technical operations are led by Chief Technology Officer Jeremy Jacob, who brings over 20 years of experience in architecting globally scalable cloud solutions and mobile enterprise applications. Financial oversight is managed by Controller Cyndi Cole, a CPA and former Deloitte auditor with 25 years of corporate finance expertise, while Jesus Davila, formerly of WellCare Health Plans, leads strategic business development. The company’s scientific and medical advisory board includes notable figures such as Yale-trained endocrinologist Dr. Reza Yavari and radiation oncologist Dr. Alex Mirakian. As of early 2026, the company has significantly cleaned its capital structure, supported by key stakeholders including Nicholas Peters, who maintains a notable 8.65% beneficial ownership stake.